Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
How do you manage hepatotoxicity thought to be related to Romosozumab use?
Have you seen liver toxicity associated with Romosozumab?
Related Questions
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Is there any concern with starting romosozumab in a patient who is taking raloxifene for a history of breast cancer?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Would you consider PTH analogue in a patient with mildly elevated PTH?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?